Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults at least 18 years of age~* Patients with signs and symptoms consistent with acute herpes zoster disease, namely, a dermatomal vesicular rash which may be preceded by pain and parasthesias in the days before vesicular eruption~* Herpes Zoster associated rash present for ≤ 72 hours~* Patients who are deemed to be immunocompetent based on history and physical exam~Exclusion Criteria:~* Females who are pregnant or nursing~* History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic, or unstable heart disease, gastrointestinal, neurological, psychiatric, renal, urological, endocrine, opthalmologic, or immune mediated disease including HIV or HBsAg positivity~* Chronic genital herpes~* Patients who received cytotoxic or immunosuppressive drug therapy within 3 months prior to study participation~* Previous vaccinations against Herpes Zoster~* Patients with \> 50% of vesicles crusted at screen~* Patients who received topical or systemic antiviral medications or immunomodulatory agents for herpes zoster viral infections or capsaicin within 4 weeks of study participation~* Patients with a history of congenital, acquired, or corticosteroid induced immunodeficiency, including malignancy, significantly impaired renal function (creatinine clearance \< 50 cc/min), and impaired hepatic function (ALT or AST levels \> 3 times the upper limit of normal)~* QTc \> 500msec~* Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir~* Patients with gastrointestinal dysfunction that might interfere with drug absorption~* Patients, considered by the investigator, for any reason, to be an unsuitable candidate for receiving the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPB-348 1000 mg (Type: EXPERIMENTAL): EPB-348 1000 mg dosed once daily for seven days
- EPB-348 2000 mg (Type: EXPERIMENTAL): EPB-348 2000 mg dosed once daily for seven days
- EPB-348 3000 mg (Type: EXPERIMENTAL): EPB-348 3000 mg dosed once daily for seven days
- Valacyclovir (Type: ACTIVE_COMPARATOR): Valacyclovir 1000 mg dosed three times daily for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).